Literature DB >> 33740864

VISUAL FIELD ASSESSMENT IN HYPERTENSION GLAUCOMA.

J Lešták, M Fůs.   

Abstract

AIMS: The aim of the work is to verify the necessity of full-field perimetry test in incipient glaucoma.
MATERIAL AND METHODS: The study included group of 16 incipient hypertension glaucoma (HTG group) patients without obvious changes in visual field and control group of 10 patients with normal ocular findings and value 1.0 of visual acuity. In both groups, full-field perimetry test was performed followed by a glaucoma perimetry test (rapid threshold strategy in both cases). Evaluated parameters were pattern defect (PD) and overall defect (OD) using Pearsons correlation coefficient.
RESULTS: Strong correlation coefficient between PD (r = 0.74) and OD (r = 0.63) of both perimetry test were found in HTG group. Moderate correlation of PD (r = 0.54) and strong correlation of OD (r = 0.64) in control group.
CONCLUSION: Results of the study shows, that expected changes of peripheral visual field will be recorded first in HTG group, but opposite is true. Perimetry glaucoma test is for incipient glaucoma sufficient to document the course and the examination of glaucoma disease.

Entities:  

Keywords:  brimonidin; hypertension glaucoma; overall defekt; pattern defect; perimetry test

Mesh:

Year:  2021        PMID: 33740864     DOI: 10.31348/2021/2

Source DB:  PubMed          Journal:  Cesk Slov Oftalmol        ISSN: 1211-9059


  3 in total

1.  Temporal Visual Field Border.

Authors:  Jan Lestak; Tomas Lestak; Martin Fus; Iva Klimesova
Journal:  Clin Ophthalmol       Date:  2021-08-03

2.  OCT angiography, RNFL and the visual field at different values of intraocular pressure.

Authors:  Jakub Kral; Jan Lestak; Elena Nutterova
Journal:  Biomed Rep       Date:  2022-03-02

3.  Comparison of the Effect on Vessel Density and RNFL between Carteolol and Latanoprost.

Authors:  Elena Nutterova; Martin Fus; Libuse Bartosova; Iva Klimesova; Jan Lestak
Journal:  J Clin Med       Date:  2022-07-18       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.